Barry Nelson describes his family’s cancer history as “prolific.”
Nelson’s grandmother, mother, and an aunt all died from cancer, and it seemed like Nelson might be next.
“One morning, I woke up and I had a pain in my neck on my left side. I went to my primary care physician and, ultimately, I found out that I had lung cancer, stage III b.” He went through several cycles of radiation and chemotherapy with standard lung cancer drugs, but none had a lasting effect and all came with painful side effects.
“Not only was I nauseous, but I also was having excruciating neuropathy and pain in my arms and sometimes in my legs. I can remember times when I would be in bed for two weeks, feel better for one week, and then back to my bed.
“My doctors initially gave me two years to live. That’s when I said I want to see a lung cancer specialist, and I came to Dana-Farber/Brigham and Women’s Cancer Center. When you get that kind of news, you want to be at a place where they have hope and where they are going to fight as hard as you fight.
“Dr. [Christopher] Lathan explained to me what I could expect when it came to how my health might need to be managed. He set real expectations for me. I have resources and people there for me, but I didn’t want to be a burden to anyone. The blessing is that my health hasn’t deteriorated, but Dr. Lathan was very real with me, and that’s what I appreciate so much about him and Dana-Farber.
“I’m a very spiritual person; I have a relationship with God. So I talked to God about my cancer. I would say, “God, I trust you. I know that you have a purpose for my life.’”
Since Oct. 2013, Nelson has been participating in a clinical trial at Dana-Farber/Brigham and Women’s Lowe Center for Thoracic Oncology of a new immune checkpoint inhibitor, one of a family of immunotherapy drugs that use the body’s own immune system to fight cancer cells. Dana-Farber’s Gordon Freeman, PhD, is one of the pioneers in the field of immunotherapy, dating back to the 1980s, and in 2000 he discovered the PD-L1 protein and its connection to the body’s immune response to cancer, giving researchers new pathways to target. Once given two years to live, Nelson is now thriving under the care of Christopher Lathan, MD, MS, MPH, and had the opportunity to meet Freeman, the scientist behind the discoveries that led to this new treatment. For more details about this discovery, download the Whitepaper.
“When I first started the [immunotherapy] drug, I immediately knew it was working. I could feel my body changing – pain, neuropathy, all those things were beginning to go away. My tumors shrunk about 25 percent immediately.
“I’ve been doing outstanding ever since. I’ve been riding my bicycle and doing everything I want to do. I don’t even feel like I’m on any type of treatment. I don’t have to be sick and lie in bed and have my life be limited. My life is full.
“When I look back at my family, that my mother died from cancer, her mother, her sister – they all went through chemotherapy and radiation like I did. But for me to be able to participate in a cutting-edge treatment that’s going to help so many other people, I feel like that’s part of what God wants for me.”